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Abstract
Purpose Retrospective evaluation of our experience with
the use of flow diverters (FD) for the endovascular treatment
of direct carotid-cavernous sinus fistulae (diCCF).
Methods Between 2011 and 2015, 14 consecutive patients
with 14 diCCF were treated with FD alone or in combina-
tion with other implants in a single institution.
Results A total of 21 sessions were performed in 14 pa-
tients. FD placement was technically successful in all cases
without an adverse event. Patients were treated with FD
alone (n = 5), FD and covered stents (n = 2), FD and coils
(n = 7). A total of 59 FD (24 Pipeline Embolization De-
vice, Medtronic; 35 p64 Flow Modulation Device, phenox),
291 coils, and 3 stent grafts were used. Three of 14 diCCF
were completely occluded after the 1st session, a minor
residual shunt was found in 7/14, and in the remaining 4/14
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patients, the shunt volume was reduced significantly. The
mean follow-up period encompassed 20 months. Additional
treatment included transvenous coil occlusion (n = 3) and/or
further FD deployment (n = 5). An asymptomatic internal
carotid artery (ICA) occlusion was encountered in 2 pa-
tients, related to an interruption of antiaggregation. At the
last follow-up, 10/14 patients were free from ocular symp-
toms (71 %), 2 had residual exophthalmos, and no patient
had clinical deterioration.
Conclusion The usage of FD for the treatment of diCCF is
straightforward. Injury of the cranial nerves can be avoided.
In most cases, ocular symptoms improve. Several FD layers
and/or an adjunctive venous coil occlusion are required.
Complete occlusion of a diCCF may take weeks or months
and long-term antiaggregation is required. In the future,
a flexible stent graft might be a better solution.




diCCF direct carotid-cavernous sinus fistula
DSA digital subtraction angiography
FD flow diverter
ICA internal carotid artery
ID inner diameter
IV intravenous MRA magnetic resonance angiogra-
phy
PO per os PTA percutaneous transluminal angioplasty
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Introduction
Carotid-cavernous sinus fistulae (CCF) in general represent
an abnormal communication between the internal and/or
external carotid arteries and the cavernous sinus, result-
ing in venous congestion of the cavernous sinus and the
adjacent veins and sinuses. Clinical presentation may in-
clude chemosis, conjunctival injection, visual impairment,
and diplopia. According to the Barrow classification, CCFs
are subdivided into four different types (A–D), depending
on flow rates, etiology, and source of feeding vessels. Di-
rect carotid-cavernous sinus fistulae (diCCF, type A) are
generally characterized by an abnormal arteriovenous com-
munication between one internal carotid artery (ICA) and
the ipsilateral cavernous sinus [1]. diCCF are typically due
to a severe blunt or penetrating head trauma [2]. Less fre-
quently they occur spontaneously in the context of vessel
wall connective tissue disease (e. g., Ehlers Danlos syn-
drome) or after the rupture of a preexisting cavernous ICA
aneurysm [3–5]. Moreover, diCCF can be a complication
following skull base surgery or endovascular procedures ad-
jacent to the cavernous segment of the ICA (e. g., balloon
angioplasty or stent placement) [6–10].
The goal of the treatment of diCCF is to occlude the
arteriovenous shunt and to preserve the patency of the con-
cerned internal carotid artery (ICA). A variety of endovas-
cular treatment strategies have been developed during the
past three decades, geared to the size and location of the fis-
tulous point, as well as to the venous outflow patterns. Ac-
cording to the classification of van Rooij et al. [5], diCCF
can further be classified with regard to the shunt volume
in high-, intermediate-, or low-flow fistulae. In high-flow
diCCF, the entire shunt volume enters the arteriovenous fis-
tula without filling of intracranial vessels. In intermediate-
flow diCCF, both the diCCF and the ipsilateral intracranial
vessels are supplied with blood from the ICA. In low-flow
diCCF, only mild arteriovenous shunting to the cavernous
sinus exists. Historically, endovascular treatment strategies
via transvenous or transarterial access routes included the
use of detachable balloons [4, 11], coils [12–14], covered
stents [15, 16], and liquid embolic agents [17, 18]. Sili-
con balloons were widely used for the treatment of diCCF
over many years, until their unexpected withdrawal from the
market in 2004. Today, detachable coils are most frequently
used. In the case of a large shunt volume, an adjunctive de-
vice such as a covered stent may be considered.
Initially, flow diverting implants were designed for the
extrasaccular treatment of complex cerebral aneurysms,
but techniques and indications for the use of FD continue
to evolve [19]. Recently published case reports showed
promising results for the treatment of diCCF with flow
diverter (FD) [20–22]. The dense coverage of FD not only
provides protection of the ICA during transvenous coil
insertion, but also enables endothelial overgrowth of the
lacerated arterial segment.
We sought to retrospectively evaluate our experiences
with the use of FD for endovascular treatment of diCCF.
Beside some sporadic case reports, this is, to the best of
our knowledge, the first case series reporting the use of FD
for the treatment of diCCF.
Materials and methods
Patient enrollment and adherence to ethical standards
Being intrigued by the capacity of FD to reconstruct dis-
eased arteries, we offered this treatment to all elective pa-
tients with diCCF who had been referred to or diagnosed
by us since April 2011. In patients with an iatrogenic
diCCF sustained during an endovascular procedure (e. g.,
stent angioplasty), the FD reconstruction of the concerned
artery was part of the bailout strategy. All patients and/or
their legal representatives were informed about the disease
and the treatment options, and declared consent in written
form. In retrospect, we analyzed all concerned case his-
tories and endovascular procedures until June 2015. The
responsible ethics committee (“Ethik-Kommission bei der
Landesärztekammer Baden-Württemberg”) issued a waiver
for ethical consultation for this retrospective data analy-
sis. For diCCF following the rupture of a cavernous ICA
aneurysm into the cavernous sinus, all currently available
FD can be used on-label. In diCCF due to an endovascu-
lar or external trauma, only p64 Flow Modulation Device
(phenox, Germany) can be applied on-label. The approved
usage of Pipeline Embolization Device (PED, Medtronic,
Ireland), flow redirection endoluminal device (FRED, Mi-
crovention, USA), and Surpass Streamline Flow Diverter
(Stryker, USA) is limited to the treatment of aneurysms.
Diagnosis of diCCF
Work-up of patients referred to us or identified as carrying
a diCCF due to typical signs and symptoms (e. g., chemosis,
exophthalmos, glaucoma, and/or progressive visual loss)
underwent CT and/or MRI/magnetic resonance angiogra-
phy (MRA) examinations of the head, according to clinical
standards. Digital subtraction angiography (DSA) includ-
ing runs with increased frame rate and manual cross com-
pression was used to confirm the diagnosis, identify the
site of the ICA tear, and understand the patterns of ve-
nous drainage. If a diCCF occurred as a complication of
an intracranial endovascular procedure, no further imaging
besides DSA was performed in order to not delay the nec-
essary treatment. Finally, all diCCF were classified into
K
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Tab. 1 Etiology of direct carotid-cavernous sinus fistulae and shunt
volume
Patient # Etiology Shunt volume
1 During stenting High
2 During stenting Intermediate
3 During stenting Low
4 Trauma Intermediate
5 During stenting Low
6 Spontaneous Intermediate
7 Trauma Intermediate




12 During stenting Low
13 Aneurysm rupture Intermediate
14 During stenting Low
high-, intermediate- and low-flow fistulae according to the
grading scale of van Rooij et al. [5].
Endovascular treatment
The technical details of the procedures followed gener-
ally accepted principles, based on the decisions of the op-
erator and/or the senior author (HH). diCCF presenting
with a small shunt volume were initially treated with FD
alone. In diCCF where the fistulous point could be iden-
tified clearly and where the ICA was not too tortuous, the
deployment of a stent graft was attempted in order to oc-
clude the fistulous point immediately. In fistulae with an
intermediate or large shunt volume, FD deployment was
combined with either transarterial or transvenous coil oc-
clusion of the cavernous sinus and the efferent veins.
Prior to FD placement, clopidogrel (single 600 mg load-
ing dose, thereafter 75 mg/d) and aspirin (single 500 mg
loading dose, thereafter 100 mg/d) were administered for
dual platelet antiaggregation. The level of platelet func-
tion inhibition was assessed using the Multiplate Analyzer
(Roche Diagnostics, Switzerland). In case of insufficient
response to clopidogrel, a second loading dose of 180 mg
ticagrelor (Brilique; AstraZeneca, United Kingdom) was
given per os (PO), followed by 2 × 90 mg ticagrelor daily
thereafter. If the diCCF occurred as a complication during
an endovascular procedure in a patient not already being
loaded or premedicated, an intravenous bolus injection of
500 mg aspirin and 180 mg ticagrelor via a gastric tube
were given, combined with a body weight-adapted intra-
venous bolus injection of eptifibatide (Integrilin; Glaxo-
SmithKline, United Kingdom). A carotid occlusion test
was performed before treatment in order to visualize the
collaterals for the concerned ICA in the event that the
sacrifice of this vessel would become necessary. Under
general anesthesia and with full relaxation, a 6F guiding
catheter was placed in the cervical segment of the concerned
ICA. Then a 0.027” ID microcatheter (e. g., Marksman, Re-
verse 27, both Medtronic; Excelsior XT27, Stryker) was
navigated over a 0.014” microguidewire (e. g., Synchro2
0.014”, Stryker) across the fistulous point to the M1 seg-
ment of the ipsilateral middle cerebral artery. For coil
occlusion a second microcatheter (e. g., Excelsior SL10,
Stryker; Echelon10, Medtronic) was placed in the cav-
ernous sinus from either the arterial or venous side, and
coil occlusion was performed before (transarterial) or after
(transvenous) the FD were deployed. The number of FD
used in each patient depended on the periprocedural evolu-
tion of the shunt reduction, based on the judgement of the
operator. When the shunt volume had been significantly
reduced, the endovascular treatment was terminated.
Follow-up and outcome
Angiographic and clinical follow-up assessment was sched-
uled 3, 6 and 12 months after the treatment, and annually
thereafter. The clinical examination was carried out by
a board-certified neurologist or neurosurgeon. Additionally,
patients were advised to immediately return to our institu-
tion in case of any clinical deterioration. The presented
data were collected retrospectively from inpatient hospital
records, radiologic reports, and DSA examinations. Angio-
graphic outcomes were categorized as “target vessel occlu-
sion”, “complete diCCF occlusion”, or “incomplete diCCF
occlusion with persistent flow of the diCCF”. Clinical out-
come was reported for every follow-up and graded into four
types: 1) full recovery from neurological symptoms, 2) im-
proved neurological symptoms, 3) unchanged neurological
symptoms, or 4) worsening of symptoms.
Results
Patients
Between April 2011 and June 2015, a total of 14 pa-
tients (3 men, 11 women; median age 59 years, age range
18–84 years) with 14 diCCF were treated with FD alone,
or in combination with coils or covered stents at a single
institution. In 2 patients the diCCF occurred spontaneously
and 4 patients had a trauma prior to the onset of symp-
toms. One patient presented with a spontaneous rupture
of a cavernous ICA aneurysm, which resulted in a diCCF.
In 7 patients the diCCF occurred as a complication of an
endovascular treatment (Tab. 1 and 2).
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(Graftmaster Coronary Stent Graft
[Abbott Vascular, USA] 1 × 4/12,
1 × 4/16)
4 × FD
(PED: 3 × 3.75/20, 1 × 4/20)
6 d: incomplete diCCF occlusion
207 d: complete diCCF occlusion
456 d: complete diCCF occlusion
None; 456 d:
ICA occlusion due to interrup-
tion of medication intake
mRS 0
#2 female, 76 years
2 procedures
Stent PTA
2 × FD (1 × PED 3/2, 1 × p64 3.5/15)
4 d: incomplete diCCF occlusion
14 d: further diCCF occlusion
161 d: complete diCCF occlusion
1210 d: complete diCCF occlusion




#3 male, 72 years
1 procedure
Stent PTA
1 FD (1 × p64 3.5/18)
134 d: complete diCCF occlusion, ISS
246 d: complete diCCF occlusion, ISS
328 d: complete diCCF occlusion, ISS
545 d: complete diCCF occlusion, ISS
One; 136 d: re-stent PTA
mRS 3 after ICA TEA, unrelated
to the diCCF
#4 female, 17 years
2 procedures
Severe head trauma
24 fibered coils, transarterial
6 × FD (5 × p64 4.5/18, 4/21, 4/18,
4/18, 4.5/15, 1 × PED 3.5/14)
5 d: incomplete diCCF occlusion
9 d: incomplete diCCF occlusion
65 d: complete diCCF occlusion
252 d: complete diCCF occlusion
One; 5 d: 4 × FD (2 × PED 3/20,
2 × p64 3/15)
mRS 0
#5 male, 60 years
1 procedure
Stent PTA
2 × FD (2 × p64 4/18)
44 d: complete diCCF occlusion
381 d: complete diCCF occlusion, ISS
457 d: complete diCCF occlusion, ISS
503 d: complete diCCF occlusion, ISS
One; 381 d: re-PTA
mRS 0
#6 female, 50 years
2 procedures
Severe head trauma
3 × FD (1 × p64: 2 × 4,5/24, 1 × p64
4/24)
7 d: incomplete diCCF occlusion
18 d: incomplete diCCF occlusion
190 d: complete diCCF occlusion
545 d: complete diCCF occlusion
One; 20 d: 3 × FD
(1 × PED 3,25/16, 2 × p64
3,5/18)
mRS 0
#7 female, 66 years
2 procedures
Severe head trauma
2 × FD (2 × PED 5/20)
65 coils, transvenous
39 d: incomplete diCCF occlusion
63 d: incomplete diCCF occlusion
125 d: complete diCCF occlusion
957 d: complete diCCF occlusion
One; 63 d: 1 × FD (1 × p64
4/18 mm); 9 coils, transvenous
mRS 1
#8 female, 44 years
1 procedure
Stent PTA
1 × SG (Graftmaster 1 × 3.5/12)
2 × FD (PED 1 × 4/20, 1 × 3.5/18)
7 d: incomplete diCCF occlusion
96 d: complete diCCF occlusion
924 d: complete diCCF occlusion
None
mRS 2, due do previous cerebral
ischemia from bilateral chronic
ICA occlusion
#9 female, 74 years
3 procedures
Spontaneous
65 fibered coils, transvenous
2 d: incomplete diCCF occlusion
26 d: incomplete diCCF occlusion
76 d: incomplete diCCF occlusion
521 d: complete diCCF occlusion
Two: 2 d: 2nd session: 8 FD
(8 × PED: 2 × 5/25, 3 × 4.75/20,
1 × 4.5/35, 2 × 5/30);
26 d: 3rd session: 20 fibered
coils, transvenous
mRS 0
#10 female, 64 years
1 procedure
Severe head trauma
3 fibered coils, transarterial
1 × FD (p64 1 × 4.5/21)
77 d: complete diCCF occlusion
658 d: complete diCCF occlusion
None
mRS 0




6 × FD (p64: 1 × 4/21, 1 × 3,5/18,
1 × 3,5/15, 1 × 4/15, 2 × 3.5/21)
2 d: incomplete diCCF occlusion
12 d: incomplete diCCF occlusion
18 d: ICA occlusion
None; 18 d:
ICA occlusion due to interrup-
tion of medication intake
mRS 1, due to the head trauma
Primary treatment results
FD placement was technically successful in all patients.
There was no adverse event related to the FD placement in
any of the patients. A total of 21 endovascular sessions were
performed in 14 patients, with a single session in 8 patients,
2 sessions in 5, and 3 sessions in 1 patient (Fig. 1). Five
patients were treated with FD alone at the first session and
2 patients with FD and covered stents. If coils were used in
combination with FD in the same session, a transarterial ap-
proach was used for coil insertion and the FD was deployed
thereafter (5 patients; Fig. 2). A primary transvenous ap-
proach for coil occlusion was used in 1 patient with a large
shunt volume. In summary, a total of 59 FD (24 × Pipeline,
Medtronic; 35 × p64, phenox), 291 bioactive detachable
K
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#12 female, 58 years
1 procedure
Stent PTA
1 × FD (PED 1 × 4/20)
73 d: complete diCCF occlusion
737 d: complete diCCF occlusion
None
mRS 0
#13 female, 86 years
1 procedure
Ruptured cavernous ICA aneurysm
8 × FD (6 × p64: 2 × 4.5/21,
1 × 4.5/18, 1 × 4.5/15, 1 × 4/18;
2 × PED: 1 × 4.5/25, 1 × 4/20)
35 coils, transvenous
142 d: complete diCCF occlusion None
mRS 1
#14 female, 46 years
2 procedures
Stent PTA
3 × FD (3 × p64 2 × 3.5/18, 1 × 4/18)
3 d: incomplete diCCF occlusion
8 d: incomplete diCCF occlusion
382 d: complete diCCF occlusion
One; 6 d:
2 × FD (2 × p64 1 × 3.5/18,
1 × 4/18)
mRS 0
All sizes are given in mm; all time intervals refer to the first treatment
diCCF direct carotid-cavernous sinus fistula, FD flow diverter, ICA internal carotid artery, ISS in-stent stenosis, mRS modified Rankin Scale,
PED Pipeline Embolization Device (Medtronic, Ireland), p64 Flow Modulation Device (phenox, Germany), PTA percutaneous transluminal
angioplasty, SG Stent Graft
coils, and three stent grafts (Graftmaster, Abbott Vascular)
were used in 21 procedures.
Of the 14 patients who underwent endovascular treat-
ment, 3 exhibited a complete occlusion of the fistula after
the initial treatment (21 %). A minor leak into the cavernous
sinus was observed in 7 patients (50 %). In 4 patients, the
shunt into the cavernous sinus was reduced significantly
(29 %). No carotid occlusion, as salvage therapy, was nec-
essary in the 14 cases. No procedural complications were
encountered.
Follow-up angiographic and clinical results
The median follow-up period encompassed 20 months
(range 5–51 months). A total of 6/14 fistulae showed
complete occlusion in the first angiographic control exam-
ination. One patient initially treated with FD alone needed
a second embolization session consisting of transvenous
coil occlusion of the cavernous sinus due to incomplete
occlusion of the fistula. Access was gained via the infe-
rior petrosal sinus. Two patients who were treated with
FD alone in the initial treatment session also underwent
a second session with additional FD placement, which led
to a complete occlusion of both fistulae. Another 2 patients
initially treated with FD and transarterial coil occlusion
of the cavernous sinus also needed a second session with
additional FD placement (n = 1) or flow diverter placement
combined with further transvenous coil occlusion (n = 1).
One patient with a high-volume fistula, initially treated with
FD alone, needed two further treatment sessions with FD
placement (second session) and transvenous coil insertion
(third session) due to a persistent arteriovenous shunt.
Two patients experienced a thrombotic occlusion of the
target ICA. In patient #1, the attempted stent percutaneous
transluminal angioplasty (PTA) of a cavernous right ICA
stenosis resulted in a diCCF, which was treated in the same
session using two Graftmaster (Abbott Vascular, USA)
and four FD. Follow-up digital subtraction angiography
7 months later confirmed the occlusion of the diCCF and
the patency of the ICA. The dual platelet inhibition was
interrupted 15 months later by another physician. MRI per-
formed at another institution 16 months after the treatment
and 1 month after the change in medication revealed the
asymptomatic occlusion of the right ICA. In patient #11,
the diCCF occurred after a severe head trauma together
with a major intracranial hemorrhage. The endovascular
procedure was carried out uneventfully several weeks later.
Early follow-up DSA prior to discharge and 18 days after
the last treatment showed thrombotic occlusion of the ICA.
Analysis of the circumstances disclosed a lack of platelet
function inhibition, related to a failure of the patient to
comply with the medication regimen.
Of the 14 patients, 10 exhibited complete resolution of
their ocular symptoms (71 %). Two patients reported resid-
ual symptoms with mild exophthalmos. No patient experi-
enced worsening of preexisting or new symptoms.
Discussion
The results of this series of patients with diCCF, treated by
FD placement with or without coil insertion, indicate that
the above-described treatment regimen is both safe and ef-
ficacious. After a median follow-up interval of 20 months,
all diCCF were occluded and no patient had worsened clini-
cally. Two patients showed an asymptomatic ICA occlusion
during the follow-up DSA due to insufficient dual platelet
antiaggregation. Nevertheless, it is a cost-intensive, ex-
traordinary treatment that is at the moment off-label if the
Pipeline embolization device is used.
The treatment of diCCF was for many years based on
the deployment of initially latex and later silicone detach-
K
C. M. Wendl et al.
Fig. 1 Spontaneous direct carotid-cavernous sinus fistula in a 50 year-old female patient (a). Deployment of three flow diverters resulted in
a significant reduction of the shunt volume (b). Significant recurrence of the arteriovenous shunt prompted a second treatment 19 d later, with
implantation of another three flow diverters (c), without an instantaneous angiographic effect. Due to a significant clinical improvement, the patient
decided to return home. Follow-up digital subtraction angiography examinations 6 months (d) and 18 months (e) later confirmed the occlusion of
the arteriovenous fistula
able balloons. After the market withdrawal of detachable
silicone balloons in 2004, latex balloons remain available
(Goldvalve, Balt Extrusion). The use of balloons for diCCF
occlusion, albeit well established, was far from ideal. The
transit of the balloon from the ICA lumen to the cavernous
sinus can be difficult if the hole in the vessel wall is small.
The inflation level of the balloon has to be well calibrated
in order to occlude the fistula without compromising the
patency of the ICA. Loss of the balloon from the micro-
catheter, displacement of the balloon during detachment,
vessel dissection, cranial nerve compression in the wall of
the cavernous sinus, and early balloon deflation are well-
known issues [4, 13, 18, 23, 24]. Hence, these issues stimu-
lated the development of numerous alternative endovascular
treatment options for diCCF. Transarterial or transvenous
coil occlusion, with or without balloon protection of the
ICA, became popular. Dense packing of the cavernous si-
nus is key for this method. A long-term outcome study from
Bink et al. in 2010 showed durable closure of CCFs and re-
liable regression of acute symptoms after coil embolization
of 19 fistulae (13 direct and 9 dural CCFs). Nevertheless,
44 % of the patients had persistent cranial nerve deficits
with disturbances of oculomotor and visual functions. The
study group ascribed these persisting deficits to the under-
lying fistula size itself and/or the space-occupying effect of
the coils, as there was a statistically significant correlation
observed between coil volume and persistent diplopia and
cranial nerve paresis [12]. To reduce the space-occupying
effect of the coils, targeted occlusion of the fistulous com-
partment of the cavernous sinus became an option. Due
to the complex anatomy of the cavernous sinus, this tech-
nique harbors the risk of incomplete fistula occlusion and
thereby aggravation of the venous pressure within the or-
bital or cortical veins. Moreover, periprocedural protrusion
of coil loops in the parent ICA could lead to thromboem-
bolic events or even inadvertent occlusion of the ICA [25,
26]. As another treatment option, covered stents (sive “stent
graft”) could be used. The Jomed Covered Stent Graft
(Jomed International AB, Sweden, [27]), the Graftmaster
Coronary Stent Graft System (Abbott Vascular) and the
latest generation of pericardium-coated stent grafts (e. g.,
AneuGraft, ITGI Medical, Israel, [28]) are basically bal-
loon-expandable stents with a covering membrane. Only
AneuGraftNx has a CE mark for neurovascular indications.
Covered stents have recently shown promising results in the
treatment of diCCF [15, 29–31]. The key issues with bal-
loon expandable stent grafts are the limited flexibility and
K
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Fig. 2 Traumatic direct carotid-cavernous sinus fistula in a 17 year-old female patient after severe head trauma (a). Chemosis, exophthalmos,
and elevated intraocular pressure were due to massive arteriovenous shunt from the right internal carotid artery (ICA) into the adjacent cavernous
sinus. Endovascular treatment in one session comprised insertion of 24 detachable coils with nylon fibers into the right superior ophthalmic vein
and the right cavernous sinus. Thereafter, six flow diverters were deployed in the cavernous segment of the right ICA, with a significant reduction
of the arteriovenous shunt (b). Early follow-up digital subtraction angiography (DSA) 6 d later revealed a residual arteriovenous shunt, which was
treated with four additional flow diverters (c). Further DSA examinations 2 months (d) and 8 months (e) after the treatment showed the occlusion
of the traumatic arteriovenous fistula (modified Rankin Scale 0)
the relatively high inflation pressure for the balloon, which
may add trauma to the already injured ICA.
The use of liquid embolic agents such as Histoacryl
(B. Braun, Germany), Onyx (Medtronic), or others for the
treatment of diCCF involves the injection of these agents
into the cavernous sinus. Uncontrolled propagation of the
embolic agent, the unintended occlusion of efferent veins,
and injury to the cranial nerves in the wall of the cavernous
sinus are reported complications [18, 32, 33].
Not least, ICA occlusion with a balloon or with coils, or
maybe with the newly available UNO Neurovascular Em-
bolization System (Medtronic) [34], remains as a second-
choice option if the anterior or posterior communicating
artery collaterals provide sufficient cross flow to the depen-
dent hemisphere.
FD are an extraordinary treatment option for diCCF,
bearing in mind that their usage in the context of diCCF
is off-label for Pipeline (Medtronic), Surpass (Stryker), and
Fred (Microvention). The p64 (phenox) can be used on-
label. In contrast to stent grafts, FD are significantly more
flexible and are therefore easier to implant. They simulta-
neously provide a dense coverage of the hole in the arterial
wall. Vessels originating from the covered part of the ICA
are still supplied with blood due to the non-sealing but flow-
diverting character of the FDs. Moreover, the vessel wall
is redefined by the FD, thereby supporting the development
of neointima. On the other hand, several disadvantages
of this method are obvious. Only 5/14 diCCF in our se-
ries were cured with FD treatment alone. Especially in the
case of a low-flow fistula, FD placement alone can lead to
complete occlusion, whereas high-flow diCCF always need
additional coil occlusion of the cavernous sinus to be cured.
Moreover, this treatment method is cost intensive and there
is often latency between FD treatment and occlusion of the
diCCF. Additionally, the necessity of stringent dual platelet
inhibition for at least several months, if not forever, is an-
other drawback of this treatment method.
A dedicated self-expanding stent graft might have the
advantage that a single implant could be sufficient, thus
reducing the costs of treatment and allowing for an instan-
taneous occlusion of the diCCF.
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Conclusion
FD deployment is a technical option for the treatment of
diCCF. The procedure per se is straightforward. A combi-
nation with coil occlusion of the cavernous sinus is possible.
The deployment of several FD and possibly several treat-
ment sessions may be necessary. Complete diCCF occlu-
sion may take several weeks. Injury to the cranial nerves in
the cavernous sinus is avoided. Most patients will improve
clinically, but strict adherence to dual platelet function in-
hibition is key. A dedicated self-expanding stent graft is the
awaited solution for several of the above-mentioned issues.
Acknowledgements The authors are most grateful to L. Bloom for the
thorough language revision of the manuscript.
Compliance with ethical guidelines
Conflict of interest M. Aguilar Pérez and H. Henkes serve as proc-
tors for ev3/Covidien/Medtronic and for phenox, and received a mod-
est remuneration. H. Henkes is cofounder and shareholder of phenox.
C.M. Wendl, R.M. Moreno, O. Ganslandt, and H. Bäzner state that
there are no conflicts of interest.
The Institutional Review Board (“Ethikkommission der Landesärztekam-
mer Baden-Württemberg”) waived consent due to the retrospective
nature of the study.
Open Access . This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Barrow DL, Spector RH, Braun IF, Landman JA, Tindall SC, Tin-
dall GT. Classification and treatment of spontaneous carotid-cav-
ernous sinus fistulas. J Neurosurg. 1985;2:248–56.
2. Gemmete JJ, Ansari SA, Gandhi D. Endovascular treatment of
carotid cavernous fistulas. Neuroimaging Clin N Am. 2009;19:
241–55.
3. Linfante I, Lin E, Knott E, Katzen B, Dabus G. Endovascular re-
pair of direct carotid-cavernous fistula in Ehlers-Danlos type IV. J
Neurointervent Surg. 2015;7:e3
4. Lewis AI, Tomsick TA, Tew JM Jr. Management of 100 consecutive
direct carotid-cavernous fistulas: results of treatment with detach-
able balloons. Neurosurgery. 1995;36:239–44.
5. van Rooij WJ, Sluzewski M, Beute GN. Ruptured cavernous si-
nus aneurysms causing carotid cavernous fistula: incidence, clini-
cal presentation, treatment, and outcome. AJNR Am J Neuroradiol.
2006;27:185–9.
6. Kalia JS, Niu T, Zaidat OO. The use of a covered stent graft for
obliteration of high-flow carotid cavernous fistula presenting with
life-threatening epistaxis. J Neurointervent Surg. 2009;1:142–5.
7. Pedersen R, Troost B, Schramm V. Carotid-cavernous sinus fistula
after external ethmoid-sphenoid surgery. Clinical course and man-
agement. Arch Otolaryngol. 1981;107:307–9.
8. Takahashi M, Killeffer F, Wison G. Iatrogenic carotid cavernous
fistula (case report). J Neurosurg. 1969;30:498–500.
9. Park HR, Yoon SM, Shim JJ, Bae HG, Yun IG. Iatrogenic carotid-
cavernous fistula after stent assisted coil embolization of posterior
communicating artery aneurysm. J Cerebrovasc Endovasc Neuro-
surg. 2015;17:43–8.
10. Yoon WK, Kim YW, Kim SR, Park IS, Kim SD, Baik MW. Transar-
terial coil embolization of a carotid-cavernous fistula which occured
during stent angioplasty. Acta Neurochir. 2009;151:849–53.
11. Xu XQ, Liu S, Zu QQ, Zhao LB, Xia JG, Zhou CG, Zhou WZ,
Shi HB. Follow-up of 58 traumatic carotid-cavernous fistulas after
endovascular detachable-balloon embolization at a single centre. J
Clin Neurol. 2013;9:83–90.
12. Bink A, Goller K, Lüchtenberg M, Neumann-Haefelin T, Dützmann
S, Zanella F, Berkefeld J, du Mesnil de Rochemont R. Long-term
outcome after coil embolization of cavernous sinus arteriovenous
fistulas. AJNR Am J Neuroradiol. 2010;31:1216–21.
13. Luo C, Teng M, Lin C, Yen D, Chang F, Chang C. Transarterial
embolization of traumatic carotid-cavernous fistulae by Gugliemi
detachable coils. A seven-year experience. Interv Neuroradiol.
2008;2:5–8.
14. De Renzis A, Nappini S, Consoli A, Renieri L, Limbucci N, Rosi A,
Vignoli C, Pellicano G, Magiafico S. Balloon-assisted coiling of the
cavernous sinus to treat direct carotid cavernous fistula. A single
center experience of 13 consecutive patients. Interv Neuroradiol.
2013;19:344–52.
15. Briganti F, Tortora F, Marseglia M, Napoli M, Cirillo L. Cov-
ered stent implantation for the treatment of direct carotid-cav-
ernous fistula and its mid-term follow-up. Interv Neuroradiol.
2009;15:185–90.
16. Li K, Dho YD, Kim KM, Kang HS, Kim JE, Hand MH. Covered
stents for the endovascular treatment of a direct carotid cavernous
fistula: Single center experiences with 10 cases. J Korean Neuro-
surg Soc. 2014;57:12–8.
17. Barber SM, Rangel-Castilla L, Zhang YJ, Klucznik R, Diaz O. Mid-
and long-term outcomes of carotid-cavernous fistula endovascular
management with Onyx and n-BCA: experience of a single tertiary
center. J Neurointervent Surg. 2014;7:762–9.
18. Luo CB, Teng MM, Chang FC, Chang CY. Transarterial balloon-
assisted n-butyl-2-cyanoacrylate embolization of direct carotid cav-
ernous fistulas. AJNR Am J Neuroradiol. 2006;27:1535–40.
19. Leung GK, Tsang AC, Lui WM. Pipeline embolization device
for intracranial aneurysm: a systematic review. Clin Neuroradiol.
2012;22:295–303.
20. Ducruet AF, Albuquerque FC, Crowley RW, McDougall CG. The
evolution of endovascular treatment of carotid cavernous fistulas:
A single-center experience. World Neurosurg. 2013;5:538–48.
21. Nadarajah M, Power M, Barry B, Wenderoth J. Treatment of a trau-
matic carotid-cavernous fistula by the sole use of a flow diverting
stent. J Neurointervent Surg. 2012;4:e1
22. Nossek E, Zumofen D, Nelson E, Raz E, Potts MB, Desousa KG,
Tanweer O, Shapiro M, Becske T, Riina HA. Use of Pipeline Em-
bolization Devices for treatment of a direct carotid-cavernous fis-
tula. Acta Neurochir. 2015;157:1125–30.
23. Lewis AI, Tomsick TA, Tew JM Jr, Lawless MA. Long-term results
in direct carotid-cavernous fistulas after treatment with detachable
balloons. J Neurosurg. 1996;84:400–4.
24. Siniluoto T, Seppänen S, Kuurne T, Wikholm G, Leinonen S,
Svendsen P. Transarterial embolization of a direct carotid cavernous
fistula with Guglielmi detachable coils. AJNR Am J Neuroradiol.
1997;18:519–23.
25. Halbach VV, Higashida RT, Barnwell SL, Dowd CF, Hieshima GB.
Transarterial platinum coil embolization of carotid cavernous fis-
tula. AJNR Am J Neuroradiol. 1991;12:429–33.
26. Klisch J, Huppertz HJ, Spetzger U, Hetzel A, Seeger W, Schu-
macher M. Transvenous treatment of carotid cavernous and dural
K
Direct carotid cavernous sinus fistulae: vessel reconstruction using flow-diverting implants
arteriovenous fistulae: results for 31 patients and review of litera-
ture. Neurosurgery. 2003;53:836–56.
27. Gercken U, Lansky AJ, Buellesfeld L, Desai K, Badereldin M,
Mueller R, Selbach G, Leon MB, Grube E. Results of the Jos-
tent coronary stent graft implantation in various clinical settings:
procedural and follow-up results. Catheter Cardiovasc Interv.
2002;56:353–60.
28. Vulev I, Klepanec A, Bazik R, Balazs T, Illes R, Steno J. Endovas-
cular treatment of internal carotid and vertebral artery aneurysms
using a novel pericardium covered stent. Interv Neuroradiol.
2012;18:164–71.
29. He XH, Li WT, Peng WJ, Lu JP, Liu Q, Rui Z. Endovascular
treatment of posttraumatic carotid-cavernous fistulas and pseudoa-
neurysms with covered stents. J Neuroimaging. 2014;24:287–91.
30. Li J, Lan Z, Xie X, You C, He M. Traumatic carotid-cavernous
fistulas treated with covered stents: experience of 12 cases. World
Neurosurg. 2010;5:514–9. doi:10.1016/j.wneu.2010.02.062.
31. Li M, Cho YD, Kim KM, Kang HS, Kim JE, Hand MH. Covered
stents for the endovascular treatment of a direct carotid cavernous
fistula: Single center experiences with 10 cases. J Korean Neuro-
surg Soc. 2015;57:2–18.
32. Elhammady MS, Wolfe SQ, Farhat H, Moftakhar R, Aziz-Sultan
MA. Onyx embolization of carotid-cavernous fistulas. J Neurosurg.
2010;112:589–94.
33. Zenteno M, Santos-Franco J, Rodriquez-Parra V, Balderrama J,
Alburto-Murrieta Y, Vega-Montesinos S, Lee A. Management of
direct carotid-cavernous sinus fistulas with the use of ethylene-
vinyl alcohol (Onyx) only: preliminary results. J Neurosurg.
2010;112:595–602.
34. Shwe Y, Paramasivam S, Ortega-Gutierrez S, Altschul D, Beren-
stein A, Fifi JT. High-flow carotid cavernous fistula and the use
of a microvascular plug system: Initial experience. Interv Neurol.
2014;3:78–84.
K
